EssilorLuxottica Acquires RetinAI to Expand AI and Data Capabilities in Vision Care
EssilorLuxottica has announced the acquisition of Ikerian AG, the Swiss health technology company operating under the RetinAI brand. While the financial terms of the transaction were not disclosed, the move adds artificial intelligence (AI) and data management capabilities to EssilorLuxottica’s growing healthcare technology portfolio.
RetinAI’s Technology and Areas of Focus
RetinAI develops AI-powered software solutions designed to support clinical, pharmaceutical, and research applications in ophthalmology. The company’s technology applies machine learning and computer vision to retinal imaging, aiming to enhance diagnostic accuracy, disease monitoring, and treatment evaluation.
The company’s core platform, RetinAI Discovery, is FDA-cleared and CE-marked. It processes large volumes of retinal images and biomarker data to assist in the assessment of conditions such as age-related macular degeneration (AMD), diabetic retinopathy, and glaucoma.
Integration with EssilorLuxottica’s Health Technology Strategy
The acquisition aligns with EssilorLuxottica’s ongoing expansion into med-tech and digitally enabled eyecare. According to the company, RetinAI’s technology will complement existing capabilities in diagnostics, treatment monitoring, and surgical tools, supporting more data-informed clinical decision-making.
“In the past year alone, we’ve made several bold moves in med-tech, all with the goal of building the most comprehensive, digitally enabled patient journey,” said Francesco Milleri, Chairman and CEO of EssilorLuxottica.
“RetinAI will add incredible value to an ecosystem that already includes comprehensive eyecare, advanced diagnostics, therapeutic innovation and surgical excellence.”
Applications in Research and Drug Development
Beyond clinical use, RetinAI collaborates with pharmaceutical companies and academic institutions to generate real-world evidence that can support clinical studies and drug development. The company’s platforms are used to analyze patient data and imaging biomarkers, with the goal of helping accelerate therapeutic research and improve trial outcomes.
“This acquisition opens an exciting new chapter for our team and technology,” said Carlos Ciller, PhD, Chairman and CEO of RetinAI.
“With EssilorLuxottica’s global reach and deep commitment to innovation, we can now bring that vision to life at an entirely new scale and level of positive impact.”
